非酒精性脂肪性肝病血清标志物研究进展*

doi:10.3969/j.issn.1672-5069.2022.02.037

Abstract

Abstract: Objective Non-alcoholic fatty liver diseases (NAFLD) is the most prevalent chronic liver disease worldwide at present, and the main mechanisms involved in the pathogenesis include insulin resistance, oxidative stress and so on. Different serum markers are closely related to the pathogenesis of NAFLD, but there is no clear conclusion yet. This article reviewed the important role of different serum markers in patients with NAFLD.

Key words: non-alcoholic fatty liver diseases, MicroRNA, Preptin, Leptin, Adiponectin, CK-18

Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.

References

[1] Kupčová V, Fedelešová M, Bulas J, et al. Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD.Int J Environ Res Pub Health,2019,16(19):3570.
[2] Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.Liver Int,2018,38 (Suppl 1):47-51.
[3] Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol,2020,5(2):167-228.
[4] Ullah R, Rauf N, Nabi G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: Recent Updates.Int J Biol Sci,2019,15(2):265-276.
[5] Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs' action through miRNA editing.Int J Mol Sci,2019,20(24):6249.
[6] Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.Hepatology,2008,48(6):1810-1820.
[7] Dongiovanni P, Meroni M, Longo M,et al. miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci,2018,19(12):3966.
[8] Liu XL, Pan Q, Zhang RN, et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.World J Gastroenterol,2016,22(44): 9844-9852.
[9] Torres LF, Cogliati B, Otton R. Green tea prevents NAFLD by modulation of miR-34a and miR-194 expression in a high-fat diet mouse model.Oxid Med Cell Longev,2019,2019:4168380.
[10] Guo XY, Chen JN, Sun F, et al. circRNA_0046367 prevents hepatoxicity of lipid peroxidation: An inhibitory role against hepatic steatosis.Oxid Med Cell Longev,2017,2017:3960197.
[11] Jia N, Lin X, Ma S, et al. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice.Nutr Metab (Lond),2018,15:86.
[12] Cai C, Lin Y, Yu C. Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: A systematic review and Meta-analysis.Can J Gastroenterol Hepatol,2019,2019: 2096161.
[13] Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.Mol Med,2019,25(1):26.
[14] Naderi M, Pazouki A, Arefian E, et al. Two triacylglycerol pathway genes, CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in hepatocytes.Arch Iran Med,2017,20(3):165-171.
[15] Sendi H, Mead I, Wan M, et al. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling.PLoS One,2018,13(7):e0200847.
[16] Akuta N, Kawamura Y, Arase Y, et al. Circulating microRNA-122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD. Hepatol Commun,2020,4(1):66-76.
[17] Lin HY, Wang FS, Yang YL,et al. MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice.Cells,2019,8(10):1298.
[18] Yang YL, Kuo HC, Wang FS,et al. MicroRNA-29a disrupts DNMT3b to ameliorate diet-induced non-alcoholic steatohepatitis in mice.Int J Mol Sci,2019,20(6):1499.
[19] Liu MX, Gao M, Li CZ, et al. Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis.Acta Pharmacol Sin,2017,38(5): 660-671.
[20] Rodrigues PM, Afonso MB, Simão AL, et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.Cell Death Dis,2017,8(4):e2748.
[21] Wang XM, Wang XY, Huang YM, et al. Role and mechanisms of action of microRNA-21 as regards the regulation of the WNT/β-catenin signaling pathway in the pathogenesis of non-alcoholic fatty liver disease.Int J Mol Med,2019,44(6):2201-2212.
[22] Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.Gut,2016,65(11):1882-1894.

Serum markers in patients with non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[2]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[3]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[4]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[5]	Wang Jia’ni, Liu Yong, Zhou Xin, et al. Predictive value of liver cirrhosis by serum microRNA-1273g-3p levels in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(4): 496-499.
[6]	Feng Juan, Halida Xiaerfuhazi, Fan Xiaotang, et al. Serum leptin level in patients with hepatitis B liver cirrhosis and concomitant metabolic associated fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 536-539.
[7]	Hao Xiaowei, Bai Na, Guo Xiaojun, et al. Correlationof serum adipocyte type fatty acid binding protein levels to glucose-lipid metabolism in patients with chronic hepatitis C and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 347-350.
[8]	Wang Songjiao , Zhang Yuchen , Gong Guofu , et al. Serum reactive oxygen species and adiponectin levels in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(2): 204-207.
[9]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.
[10]	SUN Lina, Gu Jing. Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(2): 294-296.
[11]	Xia Shujing, Zhang Lili, Zhang Xiumei, et al. Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 43-46.
[12]	Liang Xiaoli,Kuang Jisun,Liu Qiuli,et al. Therapeutic efficacy of fenofibrate at base of calorie restriction diet in the treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes [J]. Journal of Practical Hepatology, 2021, 24(1): 51-54.
[13]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[14]	Chen Lili, Fu Maoxiong, Liu Zhengjin, et al.. Changes of serum fibroblast growth factor 21 and adiponectin levels in patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2020, 23(5): 658-661.
[15]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.